Drug Information

Drug General Information
Drug ID
D0L9PA
Former ID
DIB014720
Drug Name
X-396
Synonyms
ALK inhibitors (cancer); X-276; X-353; X-376; X-396; ALK inhibitors (cancer), Xcovery; Anaplastic lymphoma kinase inhibitors (cancer), Xcovery
Drug Type
Small molecular drug
Indication Advanced solid tumor [ICD9: 140-199; ICD10:C00-C75, C7A, C7B] Phase 1/2 [523953]
Company
Xcovery
Formula
C25H25Cl2FN6O3
Canonical SMILES
CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=CC(=NN=C2N)C(=O)NC3=CC=C(C=<br />C3)C(=O)N4CCN(CC4)C
InChI
1S/C25H25Cl2FN6O3/c1-14(21-17(26)7-8-18(28)22(21)27)37-20-13-19(31-32-23(20)29)24(35)30-16-5-3-15(4-6-16)25(36)34-11-9-33(2)10-12-34/h3-8,13-14H,9-12H2,1-2H3,(H2,29,32)(H,30,35)/t14-/m1/s1
InChIKey
ONPGOSVDVDPBCY-CQSZACIVSA-N
PubChem Compound ID
56960447
PubChem Substance ID
135674224, 136920379, 172650910, 174500821, 175445211, 198965485, 240090121
Target and Pathway
Target(s) ALK tyrosine kinase receptor Target Info Inhibitor [551778]
KEGG Pathway Non-small cell lung cancer
WikiPathways Differentiation Pathway
References
Ref 523953ClinicalTrials.gov (NCT01625234) Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 551778Clinical pipeline report, company report or official report of Xcovery.